Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Gains from Investment Securities (2016 - 2025)

Viking Therapeutics' Gains from Investment Securities history spans 12 years, with the latest figure at $55000.0 for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 100.13% year-over-year to $55000.0; the TTM value through Dec 2025 reached $169000.0, up 102.41%, while the annual FY2025 figure was $55000.0, 98.84% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was $55000.0 at Viking Therapeutics, down from $5.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $388.3 million in Q4 2021 and bottomed at -$42.0 million in Q4 2024.
  • The 5-year median for Gains from Investment Securities is $1.1 million (2022), against an average of $23.6 million.
  • The largest annual shift saw Gains from Investment Securities plummeted 489.65% in 2024 before it skyrocketed 259187.85% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $388.3 million in 2021, then tumbled by 99.73% to $1.1 million in 2022, then tumbled by 771.94% to -$7.1 million in 2023, then tumbled by 489.65% to -$42.0 million in 2024, then surged by 100.13% to $55000.0 in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Gains from Investment Securities are $55000.0 (Q4 2025), $5.2 million (Q2 2025), and $5.2 million (Q1 2025).